nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLCO1B3—Mycophenolate mofetil—psoriasis	0.0767	0.114	CbGbCtD
Dabrafenib—CYP2C8—Tazarotene—psoriasis	0.0511	0.0759	CbGbCtD
Dabrafenib—SLCO1B1—Mycophenolate mofetil—psoriasis	0.0447	0.0664	CbGbCtD
Dabrafenib—ABCG2—Mycophenolate mofetil—psoriasis	0.0355	0.0527	CbGbCtD
Dabrafenib—SLCO1B1—Cyclosporine—psoriasis	0.0339	0.0503	CbGbCtD
Dabrafenib—SLCO1B3—Methotrexate—psoriasis	0.0308	0.0457	CbGbCtD
Dabrafenib—ABCG2—Hydrocortisone—psoriasis	0.0285	0.0423	CbGbCtD
Dabrafenib—ABCG2—Cyclosporine—psoriasis	0.0269	0.04	CbGbCtD
Dabrafenib—CYP2C8—Cholecalciferol—psoriasis	0.0218	0.0324	CbGbCtD
Dabrafenib—SLC22A6—Cyclosporine—psoriasis	0.0218	0.0323	CbGbCtD
Dabrafenib—CYP2C8—Mycophenolate mofetil—psoriasis	0.0189	0.0281	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—psoriasis	0.0179	0.0266	CbGbCtD
Dabrafenib—ABCG2—Dexamethasone—psoriasis	0.0177	0.0263	CbGbCtD
Dabrafenib—CYP3A4—Calcitriol—psoriasis	0.0172	0.0255	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—psoriasis	0.0165	0.0246	CbGbCtD
Dabrafenib—CYP2C8—Hydrocortisone—psoriasis	0.0152	0.0225	CbGbCtD
Dabrafenib—CYP2C8—Cyclosporine—psoriasis	0.0143	0.0213	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—psoriasis	0.0142	0.0211	CbGbCtD
Dabrafenib—CYP3A4—Methoxsalen—psoriasis	0.0134	0.0198	CbGbCtD
Dabrafenib—ABCB1—Mycophenolate mofetil—psoriasis	0.0128	0.019	CbGbCtD
Dabrafenib—SLC22A6—Methotrexate—psoriasis	0.0115	0.0171	CbGbCtD
Dabrafenib—ABCB1—Betamethasone—psoriasis	0.011	0.0163	CbGbCtD
Dabrafenib—ABCB1—Prednisolone—psoriasis	0.0108	0.0161	CbGbCtD
Dabrafenib—ABCB1—Hydrocortisone—psoriasis	0.0103	0.0153	CbGbCtD
Dabrafenib—ABCB1—Prednisone—psoriasis	0.0102	0.0152	CbGbCtD
Dabrafenib—ABCB1—Cyclosporine—psoriasis	0.0097	0.0144	CbGbCtD
Dabrafenib—CYP2C8—Dexamethasone—psoriasis	0.00944	0.014	CbGbCtD
Dabrafenib—CYP3A4—Cholecalciferol—psoriasis	0.00885	0.0131	CbGbCtD
Dabrafenib—CYP3A4—Mycophenolate mofetil—psoriasis	0.00767	0.0114	CbGbCtD
Dabrafenib—CYP3A4—Triamcinolone—psoriasis	0.00767	0.0114	CbGbCtD
Dabrafenib—CYP3A4—Betamethasone—psoriasis	0.00658	0.00977	CbGbCtD
Dabrafenib—CYP3A4—Prednisolone—psoriasis	0.00649	0.00964	CbGbCtD
Dabrafenib—ABCB1—Dexamethasone—psoriasis	0.00639	0.00949	CbGbCtD
Dabrafenib—CYP3A4—Hydrocortisone—psoriasis	0.00616	0.00914	CbGbCtD
Dabrafenib—CYP3A4—Prednisone—psoriasis	0.00613	0.0091	CbGbCtD
Dabrafenib—CYP3A4—Cyclosporine—psoriasis	0.00581	0.00863	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—psoriasis	0.00513	0.00762	CbGbCtD
Dabrafenib—CYP3A4—Dexamethasone—psoriasis	0.00383	0.00568	CbGbCtD
Dabrafenib—Abdominal discomfort—Methotrexate—psoriasis	0.000115	0.000475	CcSEcCtD
Dabrafenib—Haemorrhage—Prednisone—psoriasis	0.000115	0.000474	CcSEcCtD
Dabrafenib—Rash—Hydroxyurea—psoriasis	0.000115	0.000474	CcSEcCtD
Dabrafenib—Erythema—Dexamethasone—psoriasis	0.000115	0.000474	CcSEcCtD
Dabrafenib—Erythema—Betamethasone—psoriasis	0.000115	0.000474	CcSEcCtD
Dabrafenib—Dermatitis—Hydroxyurea—psoriasis	0.000115	0.000474	CcSEcCtD
Dabrafenib—Myalgia—Hydrocortisone—psoriasis	0.000115	0.000472	CcSEcCtD
Dabrafenib—Headache—Hydroxyurea—psoriasis	0.000114	0.000471	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000114	0.000469	CcSEcCtD
Dabrafenib—Connective tissue disorder—Prednisone—psoriasis	0.000113	0.000466	CcSEcCtD
Dabrafenib—Hypotension—Mycophenolate mofetil—psoriasis	0.000113	0.000464	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000113	0.000464	CcSEcCtD
Dabrafenib—Oedema—Prednisolone—psoriasis	0.000113	0.000464	CcSEcCtD
Dabrafenib—Neutropenia—Methotrexate—psoriasis	0.000112	0.000463	CcSEcCtD
Dabrafenib—Insomnia—Cyclosporine—psoriasis	0.000112	0.000461	CcSEcCtD
Dabrafenib—Cough—Triamcinolone—psoriasis	0.000111	0.000456	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.00011	0.000453	CcSEcCtD
Dabrafenib—Oedema—Hydrocortisone—psoriasis	0.00011	0.000453	CcSEcCtD
Dabrafenib—Asthenia—Mycophenolic acid—psoriasis	0.00011	0.000452	CcSEcCtD
Dabrafenib—Hypertension—Triamcinolone—psoriasis	0.00011	0.000451	CcSEcCtD
Dabrafenib—Infection—Hydrocortisone—psoriasis	0.000109	0.00045	CcSEcCtD
Dabrafenib—Insomnia—Mycophenolate mofetil—psoriasis	0.000109	0.00045	CcSEcCtD
Dabrafenib—Hyperhidrosis—Prednisolone—psoriasis	0.000109	0.000448	CcSEcCtD
Dabrafenib—Nausea—Hydroxyurea—psoriasis	0.000108	0.000447	CcSEcCtD
Dabrafenib—Pruritus—Mycophenolic acid—psoriasis	0.000108	0.000446	CcSEcCtD
Dabrafenib—Myalgia—Triamcinolone—psoriasis	0.000108	0.000445	CcSEcCtD
Dabrafenib—Nervous system disorder—Hydrocortisone—psoriasis	0.000108	0.000444	CcSEcCtD
Dabrafenib—Eye disorder—Prednisone—psoriasis	0.000108	0.000443	CcSEcCtD
Dabrafenib—Decreased appetite—Cyclosporine—psoriasis	0.000108	0.000443	CcSEcCtD
Dabrafenib—Infestation NOS—Methotrexate—psoriasis	0.000107	0.000442	CcSEcCtD
Dabrafenib—Infestation—Methotrexate—psoriasis	0.000107	0.000442	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000107	0.00044	CcSEcCtD
Dabrafenib—Skin disorder—Hydrocortisone—psoriasis	0.000107	0.00044	CcSEcCtD
Dabrafenib—Fatigue—Cyclosporine—psoriasis	0.000107	0.000439	CcSEcCtD
Dabrafenib—Hyperhidrosis—Hydrocortisone—psoriasis	0.000106	0.000438	CcSEcCtD
Dabrafenib—Constipation—Cyclosporine—psoriasis	0.000106	0.000436	CcSEcCtD
Dabrafenib—Dry mouth—Triamcinolone—psoriasis	0.000106	0.000435	CcSEcCtD
Dabrafenib—Renal failure—Methotrexate—psoriasis	0.000105	0.000434	CcSEcCtD
Dabrafenib—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000105	0.000432	CcSEcCtD
Dabrafenib—Diarrhoea—Mycophenolic acid—psoriasis	0.000105	0.000431	CcSEcCtD
Dabrafenib—Stomatitis—Methotrexate—psoriasis	0.000104	0.00043	CcSEcCtD
Dabrafenib—Angiopathy—Prednisone—psoriasis	0.000104	0.00043	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000104	0.000429	CcSEcCtD
Dabrafenib—Immune system disorder—Prednisone—psoriasis	0.000104	0.000428	CcSEcCtD
Dabrafenib—Oedema—Triamcinolone—psoriasis	0.000104	0.000426	CcSEcCtD
Dabrafenib—Constipation—Mycophenolate mofetil—psoriasis	0.000103	0.000425	CcSEcCtD
Dabrafenib—Arrhythmia—Prednisone—psoriasis	0.000103	0.000424	CcSEcCtD
Dabrafenib—Infection—Triamcinolone—psoriasis	0.000103	0.000424	CcSEcCtD
Dabrafenib—Hypotension—Hydrocortisone—psoriasis	0.000103	0.000423	CcSEcCtD
Dabrafenib—Haematuria—Methotrexate—psoriasis	0.000102	0.000421	CcSEcCtD
Dabrafenib—Insomnia—Prednisolone—psoriasis	0.000102	0.000419	CcSEcCtD
Dabrafenib—Alopecia—Prednisone—psoriasis	0.000102	0.000419	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Cyclosporine—psoriasis	0.000101	0.000417	CcSEcCtD
Dabrafenib—Dizziness—Mycophenolic acid—psoriasis	0.000101	0.000417	CcSEcCtD
Dabrafenib—Epistaxis—Methotrexate—psoriasis	0.000101	0.000416	CcSEcCtD
Dabrafenib—Mental disorder—Prednisone—psoriasis	0.000101	0.000415	CcSEcCtD
Dabrafenib—Erythema—Prednisone—psoriasis	0.0001	0.000413	CcSEcCtD
Dabrafenib—Malnutrition—Prednisone—psoriasis	0.0001	0.000413	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.0001	0.000413	CcSEcCtD
Dabrafenib—Hyperhidrosis—Triamcinolone—psoriasis	0.0001	0.000412	CcSEcCtD
Dabrafenib—Insomnia—Hydrocortisone—psoriasis	9.94e-05	0.00041	CcSEcCtD
Dabrafenib—Hypertension—Dexamethasone—psoriasis	9.94e-05	0.000409	CcSEcCtD
Dabrafenib—Hypertension—Betamethasone—psoriasis	9.94e-05	0.000409	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	9.87e-05	0.000406	CcSEcCtD
Dabrafenib—Myalgia—Dexamethasone—psoriasis	9.8e-05	0.000404	CcSEcCtD
Dabrafenib—Myalgia—Betamethasone—psoriasis	9.8e-05	0.000404	CcSEcCtD
Dabrafenib—Abdominal pain—Cyclosporine—psoriasis	9.78e-05	0.000403	CcSEcCtD
Dabrafenib—Body temperature increased—Cyclosporine—psoriasis	9.78e-05	0.000403	CcSEcCtD
Dabrafenib—Vomiting—Mycophenolic acid—psoriasis	9.72e-05	0.0004	CcSEcCtD
Dabrafenib—Haemoglobin—Methotrexate—psoriasis	9.67e-05	0.000398	CcSEcCtD
Dabrafenib—Rash—Mycophenolic acid—psoriasis	9.64e-05	0.000397	CcSEcCtD
Dabrafenib—Dermatitis—Mycophenolic acid—psoriasis	9.63e-05	0.000397	CcSEcCtD
Dabrafenib—Haemorrhage—Methotrexate—psoriasis	9.62e-05	0.000396	CcSEcCtD
Dabrafenib—Headache—Mycophenolic acid—psoriasis	9.58e-05	0.000395	CcSEcCtD
Dabrafenib—Decreased appetite—Hydrocortisone—psoriasis	9.56e-05	0.000394	CcSEcCtD
Dabrafenib—Body temperature increased—Mycophenolate mofetil—psoriasis	9.54e-05	0.000393	CcSEcCtD
Dabrafenib—Abdominal pain—Mycophenolate mofetil—psoriasis	9.54e-05	0.000393	CcSEcCtD
Dabrafenib—Urinary tract disorder—Methotrexate—psoriasis	9.5e-05	0.000391	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Hydrocortisone—psoriasis	9.49e-05	0.000391	CcSEcCtD
Dabrafenib—Fatigue—Hydrocortisone—psoriasis	9.48e-05	0.00039	CcSEcCtD
Dabrafenib—Vision blurred—Prednisone—psoriasis	9.45e-05	0.000389	CcSEcCtD
Dabrafenib—Urethral disorder—Methotrexate—psoriasis	9.43e-05	0.000389	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Triamcinolone—psoriasis	9.43e-05	0.000388	CcSEcCtD
Dabrafenib—Oedema—Betamethasone—psoriasis	9.39e-05	0.000387	CcSEcCtD
Dabrafenib—Oedema—Dexamethasone—psoriasis	9.39e-05	0.000387	CcSEcCtD
Dabrafenib—Insomnia—Triamcinolone—psoriasis	9.36e-05	0.000386	CcSEcCtD
Dabrafenib—Infection—Betamethasone—psoriasis	9.33e-05	0.000384	CcSEcCtD
Dabrafenib—Infection—Dexamethasone—psoriasis	9.33e-05	0.000384	CcSEcCtD
Dabrafenib—Anaemia—Prednisone—psoriasis	9.26e-05	0.000382	CcSEcCtD
Dabrafenib—Nervous system disorder—Dexamethasone—psoriasis	9.21e-05	0.000379	CcSEcCtD
Dabrafenib—Nervous system disorder—Betamethasone—psoriasis	9.21e-05	0.000379	CcSEcCtD
Dabrafenib—Thrombocytopenia—Dexamethasone—psoriasis	9.2e-05	0.000379	CcSEcCtD
Dabrafenib—Thrombocytopenia—Betamethasone—psoriasis	9.2e-05	0.000379	CcSEcCtD
Dabrafenib—Hypersensitivity—Cyclosporine—psoriasis	9.12e-05	0.000375	CcSEcCtD
Dabrafenib—Nausea—Mycophenolic acid—psoriasis	9.08e-05	0.000374	CcSEcCtD
Dabrafenib—Hyperhidrosis—Dexamethasone—psoriasis	9.08e-05	0.000374	CcSEcCtD
Dabrafenib—Hyperhidrosis—Betamethasone—psoriasis	9.08e-05	0.000374	CcSEcCtD
Dabrafenib—Eye disorder—Methotrexate—psoriasis	8.99e-05	0.00037	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Hydrocortisone—psoriasis	8.99e-05	0.00037	CcSEcCtD
Dabrafenib—Fatigue—Triamcinolone—psoriasis	8.93e-05	0.000368	CcSEcCtD
Dabrafenib—Hypersensitivity—Mycophenolate mofetil—psoriasis	8.89e-05	0.000366	CcSEcCtD
Dabrafenib—Asthenia—Cyclosporine—psoriasis	8.88e-05	0.000366	CcSEcCtD
Dabrafenib—Hypotension—Betamethasone—psoriasis	8.78e-05	0.000362	CcSEcCtD
Dabrafenib—Hypotension—Dexamethasone—psoriasis	8.78e-05	0.000362	CcSEcCtD
Dabrafenib—Pruritus—Cyclosporine—psoriasis	8.75e-05	0.000361	CcSEcCtD
Dabrafenib—Angiopathy—Methotrexate—psoriasis	8.73e-05	0.00036	CcSEcCtD
Dabrafenib—Immune system disorder—Methotrexate—psoriasis	8.69e-05	0.000358	CcSEcCtD
Dabrafenib—Abdominal pain—Hydrocortisone—psoriasis	8.69e-05	0.000358	CcSEcCtD
Dabrafenib—Body temperature increased—Hydrocortisone—psoriasis	8.69e-05	0.000358	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—psoriasis	8.67e-05	0.000357	CcSEcCtD
Dabrafenib—Asthenia—Mycophenolate mofetil—psoriasis	8.66e-05	0.000357	CcSEcCtD
Dabrafenib—Hypertension—Prednisone—psoriasis	8.65e-05	0.000356	CcSEcCtD
Dabrafenib—Chills—Methotrexate—psoriasis	8.63e-05	0.000356	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Betamethasone—psoriasis	8.56e-05	0.000352	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Dexamethasone—psoriasis	8.56e-05	0.000352	CcSEcCtD
Dabrafenib—Pruritus—Mycophenolate mofetil—psoriasis	8.54e-05	0.000352	CcSEcCtD
Dabrafenib—Myalgia—Prednisone—psoriasis	8.53e-05	0.000351	CcSEcCtD
Dabrafenib—Arthralgia—Prednisone—psoriasis	8.53e-05	0.000351	CcSEcCtD
Dabrafenib—Alopecia—Methotrexate—psoriasis	8.5e-05	0.00035	CcSEcCtD
Dabrafenib—Insomnia—Betamethasone—psoriasis	8.5e-05	0.00035	CcSEcCtD
Dabrafenib—Insomnia—Dexamethasone—psoriasis	8.5e-05	0.00035	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	8.48e-05	0.000349	CcSEcCtD
Dabrafenib—Diarrhoea—Cyclosporine—psoriasis	8.47e-05	0.000349	CcSEcCtD
Dabrafenib—Mental disorder—Methotrexate—psoriasis	8.43e-05	0.000347	CcSEcCtD
Dabrafenib—Erythema—Methotrexate—psoriasis	8.38e-05	0.000345	CcSEcCtD
Dabrafenib—Malnutrition—Methotrexate—psoriasis	8.38e-05	0.000345	CcSEcCtD
Dabrafenib—Hypersensitivity—Prednisolone—psoriasis	8.29e-05	0.000342	CcSEcCtD
Dabrafenib—Diarrhoea—Mycophenolate mofetil—psoriasis	8.26e-05	0.00034	CcSEcCtD
Dabrafenib—Body temperature increased—Triamcinolone—psoriasis	8.18e-05	0.000337	CcSEcCtD
Dabrafenib—Dizziness—Cyclosporine—psoriasis	8.18e-05	0.000337	CcSEcCtD
Dabrafenib—Oedema—Prednisone—psoriasis	8.18e-05	0.000337	CcSEcCtD
Dabrafenib—Decreased appetite—Dexamethasone—psoriasis	8.17e-05	0.000336	CcSEcCtD
Dabrafenib—Decreased appetite—Betamethasone—psoriasis	8.17e-05	0.000336	CcSEcCtD
Dabrafenib—Infection—Prednisone—psoriasis	8.13e-05	0.000335	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Dexamethasone—psoriasis	8.11e-05	0.000334	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Betamethasone—psoriasis	8.11e-05	0.000334	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—psoriasis	8.1e-05	0.000334	CcSEcCtD
Dabrafenib—Hypersensitivity—Hydrocortisone—psoriasis	8.1e-05	0.000334	CcSEcCtD
Dabrafenib—Fatigue—Dexamethasone—psoriasis	8.1e-05	0.000334	CcSEcCtD
Dabrafenib—Fatigue—Betamethasone—psoriasis	8.1e-05	0.000334	CcSEcCtD
Dabrafenib—Nervous system disorder—Prednisone—psoriasis	8.02e-05	0.00033	CcSEcCtD
Dabrafenib—Dizziness—Mycophenolate mofetil—psoriasis	7.98e-05	0.000329	CcSEcCtD
Dabrafenib—Skin disorder—Prednisone—psoriasis	7.95e-05	0.000327	CcSEcCtD
Dabrafenib—Hyperhidrosis—Prednisone—psoriasis	7.91e-05	0.000326	CcSEcCtD
Dabrafenib—Vision blurred—Methotrexate—psoriasis	7.9e-05	0.000325	CcSEcCtD
Dabrafenib—Asthenia—Hydrocortisone—psoriasis	7.89e-05	0.000325	CcSEcCtD
Dabrafenib—Vomiting—Cyclosporine—psoriasis	7.87e-05	0.000324	CcSEcCtD
Dabrafenib—Rash—Cyclosporine—psoriasis	7.8e-05	0.000321	CcSEcCtD
Dabrafenib—Dermatitis—Cyclosporine—psoriasis	7.79e-05	0.000321	CcSEcCtD
Dabrafenib—Pruritus—Hydrocortisone—psoriasis	7.78e-05	0.00032	CcSEcCtD
Dabrafenib—Headache—Cyclosporine—psoriasis	7.75e-05	0.000319	CcSEcCtD
Dabrafenib—Anaemia—Methotrexate—psoriasis	7.74e-05	0.000319	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dexamethasone—psoriasis	7.68e-05	0.000316	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Betamethasone—psoriasis	7.68e-05	0.000316	CcSEcCtD
Dabrafenib—Vomiting—Mycophenolate mofetil—psoriasis	7.67e-05	0.000316	CcSEcCtD
Dabrafenib—Hypersensitivity—Triamcinolone—psoriasis	7.63e-05	0.000314	CcSEcCtD
Dabrafenib—Rash—Mycophenolate mofetil—psoriasis	7.61e-05	0.000313	CcSEcCtD
Dabrafenib—Dermatitis—Mycophenolate mofetil—psoriasis	7.6e-05	0.000313	CcSEcCtD
Dabrafenib—Headache—Mycophenolate mofetil—psoriasis	7.56e-05	0.000311	CcSEcCtD
Dabrafenib—Diarrhoea—Hydrocortisone—psoriasis	7.52e-05	0.00031	CcSEcCtD
Dabrafenib—Leukopenia—Methotrexate—psoriasis	7.5e-05	0.000309	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Prednisone—psoriasis	7.45e-05	0.000307	CcSEcCtD
Dabrafenib—Dizziness—Prednisolone—psoriasis	7.44e-05	0.000307	CcSEcCtD
Dabrafenib—Asthenia—Triamcinolone—psoriasis	7.43e-05	0.000306	CcSEcCtD
Dabrafenib—Body temperature increased—Dexamethasone—psoriasis	7.43e-05	0.000306	CcSEcCtD
Dabrafenib—Abdominal pain—Dexamethasone—psoriasis	7.43e-05	0.000306	CcSEcCtD
Dabrafenib—Abdominal pain—Betamethasone—psoriasis	7.43e-05	0.000306	CcSEcCtD
Dabrafenib—Body temperature increased—Betamethasone—psoriasis	7.43e-05	0.000306	CcSEcCtD
Dabrafenib—Insomnia—Prednisone—psoriasis	7.4e-05	0.000305	CcSEcCtD
Dabrafenib—Nausea—Cyclosporine—psoriasis	7.35e-05	0.000303	CcSEcCtD
Dabrafenib—Pruritus—Triamcinolone—psoriasis	7.32e-05	0.000302	CcSEcCtD
Dabrafenib—Cough—Methotrexate—psoriasis	7.31e-05	0.000301	CcSEcCtD
Dabrafenib—Dizziness—Hydrocortisone—psoriasis	7.27e-05	0.000299	CcSEcCtD
Dabrafenib—Nausea—Mycophenolate mofetil—psoriasis	7.17e-05	0.000295	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—psoriasis	7.13e-05	0.000294	CcSEcCtD
Dabrafenib—Myalgia—Methotrexate—psoriasis	7.13e-05	0.000294	CcSEcCtD
Dabrafenib—Decreased appetite—Prednisone—psoriasis	7.11e-05	0.000293	CcSEcCtD
Dabrafenib—Rash—Prednisolone—psoriasis	7.1e-05	0.000292	CcSEcCtD
Dabrafenib—Dermatitis—Prednisolone—psoriasis	7.09e-05	0.000292	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	7.08e-05	0.000292	CcSEcCtD
Dabrafenib—Fatigue—Prednisone—psoriasis	7.05e-05	0.00029	CcSEcCtD
Dabrafenib—Headache—Prednisolone—psoriasis	7.05e-05	0.00029	CcSEcCtD
Dabrafenib—Constipation—Prednisone—psoriasis	7e-05	0.000288	CcSEcCtD
Dabrafenib—Vomiting—Hydrocortisone—psoriasis	6.99e-05	0.000288	CcSEcCtD
Dabrafenib—Rash—Hydrocortisone—psoriasis	6.93e-05	0.000286	CcSEcCtD
Dabrafenib—Dermatitis—Hydrocortisone—psoriasis	6.93e-05	0.000285	CcSEcCtD
Dabrafenib—Headache—Hydrocortisone—psoriasis	6.89e-05	0.000284	CcSEcCtD
Dabrafenib—Dizziness—Triamcinolone—psoriasis	6.85e-05	0.000282	CcSEcCtD
Dabrafenib—Infection—Methotrexate—psoriasis	6.79e-05	0.00028	CcSEcCtD
Dabrafenib—Asthenia—Betamethasone—psoriasis	6.74e-05	0.000278	CcSEcCtD
Dabrafenib—Asthenia—Dexamethasone—psoriasis	6.74e-05	0.000278	CcSEcCtD
Dabrafenib—Nervous system disorder—Methotrexate—psoriasis	6.71e-05	0.000276	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—psoriasis	6.69e-05	0.000276	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Prednisone—psoriasis	6.69e-05	0.000276	CcSEcCtD
Dabrafenib—Nausea—Prednisolone—psoriasis	6.69e-05	0.000275	CcSEcCtD
Dabrafenib—Pruritus—Betamethasone—psoriasis	6.65e-05	0.000274	CcSEcCtD
Dabrafenib—Pruritus—Dexamethasone—psoriasis	6.65e-05	0.000274	CcSEcCtD
Dabrafenib—Skin disorder—Methotrexate—psoriasis	6.64e-05	0.000274	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methotrexate—psoriasis	6.61e-05	0.000272	CcSEcCtD
Dabrafenib—Vomiting—Triamcinolone—psoriasis	6.58e-05	0.000271	CcSEcCtD
Dabrafenib—Nausea—Hydrocortisone—psoriasis	6.53e-05	0.000269	CcSEcCtD
Dabrafenib—Rash—Triamcinolone—psoriasis	6.53e-05	0.000269	CcSEcCtD
Dabrafenib—Dermatitis—Triamcinolone—psoriasis	6.52e-05	0.000269	CcSEcCtD
Dabrafenib—Headache—Triamcinolone—psoriasis	6.49e-05	0.000267	CcSEcCtD
Dabrafenib—Body temperature increased—Prednisone—psoriasis	6.47e-05	0.000266	CcSEcCtD
Dabrafenib—Abdominal pain—Prednisone—psoriasis	6.47e-05	0.000266	CcSEcCtD
Dabrafenib—Diarrhoea—Betamethasone—psoriasis	6.43e-05	0.000265	CcSEcCtD
Dabrafenib—Diarrhoea—Dexamethasone—psoriasis	6.43e-05	0.000265	CcSEcCtD
Dabrafenib—Hypotension—Methotrexate—psoriasis	6.39e-05	0.000263	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—psoriasis	6.23e-05	0.000257	CcSEcCtD
Dabrafenib—Dizziness—Betamethasone—psoriasis	6.21e-05	0.000256	CcSEcCtD
Dabrafenib—Dizziness—Dexamethasone—psoriasis	6.21e-05	0.000256	CcSEcCtD
Dabrafenib—Insomnia—Methotrexate—psoriasis	6.18e-05	0.000255	CcSEcCtD
Dabrafenib—Nausea—Triamcinolone—psoriasis	6.15e-05	0.000253	CcSEcCtD
Dabrafenib—LIMK1—Innate Immune System—JUN—psoriasis	6.13e-05	0.000733	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HCAR2—psoriasis	6.12e-05	0.000732	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—VEGFA—psoriasis	6.06e-05	0.000725	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	6.04e-05	0.000722	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Prednisone—psoriasis	6.03e-05	0.000248	CcSEcCtD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	6.02e-05	0.00072	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—STAT3—psoriasis	6e-05	0.000718	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—DDX58—psoriasis	5.99e-05	0.000716	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HLA-DRB1—psoriasis	5.99e-05	0.000716	CbGpPWpGaD
Dabrafenib—Vomiting—Dexamethasone—psoriasis	5.97e-05	0.000246	CcSEcCtD
Dabrafenib—Vomiting—Betamethasone—psoriasis	5.97e-05	0.000246	CcSEcCtD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—TYK2—psoriasis	5.97e-05	0.000714	CbGpPWpGaD
Dabrafenib—Decreased appetite—Methotrexate—psoriasis	5.94e-05	0.000245	CcSEcCtD
Dabrafenib—RAF1—IRS-mediated signalling—IL6—psoriasis	5.93e-05	0.000709	CbGpPWpGaD
Dabrafenib—Rash—Dexamethasone—psoriasis	5.92e-05	0.000244	CcSEcCtD
Dabrafenib—Rash—Betamethasone—psoriasis	5.92e-05	0.000244	CcSEcCtD
Dabrafenib—Dermatitis—Betamethasone—psoriasis	5.92e-05	0.000244	CcSEcCtD
Dabrafenib—Dermatitis—Dexamethasone—psoriasis	5.92e-05	0.000244	CcSEcCtD
Dabrafenib—RAF1—Insulin Signaling—JUN—psoriasis	5.92e-05	0.000707	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—TP53—psoriasis	5.91e-05	0.000707	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CRP—psoriasis	5.91e-05	0.000706	CbGpPWpGaD
Dabrafenib—Gastrointestinal disorder—Methotrexate—psoriasis	5.9e-05	0.000243	CcSEcCtD
Dabrafenib—LIMK1—Innate Immune System—NFKB1—psoriasis	5.9e-05	0.000705	CbGpPWpGaD
Dabrafenib—Fatigue—Methotrexate—psoriasis	5.89e-05	0.000243	CcSEcCtD
Dabrafenib—Headache—Dexamethasone—psoriasis	5.89e-05	0.000242	CcSEcCtD
Dabrafenib—Headache—Betamethasone—psoriasis	5.89e-05	0.000242	CcSEcCtD
Dabrafenib—LIMK1—Axon guidance—IL6—psoriasis	5.88e-05	0.000703	CbGpPWpGaD
Dabrafenib—Asthenia—Prednisone—psoriasis	5.87e-05	0.000242	CcSEcCtD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—JUN—psoriasis	5.86e-05	0.0007	CbGpPWpGaD
Dabrafenib—Pruritus—Prednisone—psoriasis	5.79e-05	0.000238	CcSEcCtD
Dabrafenib—ABCG2—Metabolism—CYP2S1—psoriasis	5.78e-05	0.000691	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	5.77e-05	0.00069	CbGpPWpGaD
Dabrafenib—RAF1—IRS-related events—IL6—psoriasis	5.77e-05	0.000689	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—ICAM1—psoriasis	5.75e-05	0.000687	CbGpPWpGaD
Dabrafenib—RAF1—IRS-related events triggered by IGF1R—IL6—psoriasis	5.72e-05	0.000683	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—JUN—psoriasis	5.69e-05	0.00068	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IFNG—psoriasis	5.68e-05	0.000679	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	5.67e-05	0.000677	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—IL6—psoriasis	5.66e-05	0.000677	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—STAT3—psoriasis	5.66e-05	0.000677	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HLA-DRB1—psoriasis	5.66e-05	0.000676	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—NFKBIA—psoriasis	5.61e-05	0.00067	CbGpPWpGaD
Dabrafenib—Diarrhoea—Prednisone—psoriasis	5.6e-05	0.000231	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methotrexate—psoriasis	5.59e-05	0.00023	CcSEcCtD
Dabrafenib—Nausea—Dexamethasone—psoriasis	5.58e-05	0.00023	CcSEcCtD
Dabrafenib—Nausea—Betamethasone—psoriasis	5.58e-05	0.00023	CcSEcCtD
Dabrafenib—RAF1—Innate Immune System—HLA-E—psoriasis	5.57e-05	0.000666	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—STAT3—psoriasis	5.57e-05	0.000666	CbGpPWpGaD
Dabrafenib—RAF1—Insulin receptor signalling cascade—IL6—psoriasis	5.57e-05	0.000665	CbGpPWpGaD
Dabrafenib—RAF1—IGF1R signaling cascade—IL6—psoriasis	5.57e-05	0.000665	CbGpPWpGaD
Dabrafenib—RAF1—TNF alpha Signaling Pathway—IL6—psoriasis	5.57e-05	0.000665	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—NFKB1—psoriasis	5.48e-05	0.000655	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—TP53—psoriasis	5.47e-05	0.000654	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—JUN—psoriasis	5.46e-05	0.000652	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TP53—psoriasis	5.43e-05	0.000649	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—ICAM1—psoriasis	5.43e-05	0.000649	CbGpPWpGaD
Dabrafenib—Dizziness—Prednisone—psoriasis	5.41e-05	0.000223	CcSEcCtD
Dabrafenib—Body temperature increased—Methotrexate—psoriasis	5.4e-05	0.000223	CcSEcCtD
Dabrafenib—Abdominal pain—Methotrexate—psoriasis	5.4e-05	0.000223	CcSEcCtD
Dabrafenib—LIMK1—Immune System—NFKBIA—psoriasis	5.39e-05	0.000644	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL20—psoriasis	5.38e-05	0.000644	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-E—psoriasis	5.35e-05	0.000639	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TAGAP—psoriasis	5.31e-05	0.000635	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—CXCL8—psoriasis	5.28e-05	0.000631	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	5.25e-05	0.000628	CbGpPWpGaD
Dabrafenib—Vomiting—Prednisone—psoriasis	5.2e-05	0.000214	CcSEcCtD
Dabrafenib—LIMK1—Developmental Biology—TNF—psoriasis	5.2e-05	0.000621	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—NFKB1—psoriasis	5.17e-05	0.000618	CbGpPWpGaD
Dabrafenib—Rash—Prednisone—psoriasis	5.16e-05	0.000212	CcSEcCtD
Dabrafenib—RAF1—Focal Adhesion—JUN—psoriasis	5.16e-05	0.000616	CbGpPWpGaD
Dabrafenib—Dermatitis—Prednisone—psoriasis	5.15e-05	0.000212	CcSEcCtD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	5.13e-05	0.000614	CbGpPWpGaD
Dabrafenib—Headache—Prednisone—psoriasis	5.13e-05	0.000211	CcSEcCtD
Dabrafenib—BRAF—Signaling by FGFR—IL6—psoriasis	5.12e-05	0.000612	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—STAT3—psoriasis	5.09e-05	0.000609	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—STAT3—psoriasis	5.07e-05	0.000606	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Methotrexate—psoriasis	5.04e-05	0.000207	CcSEcCtD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IL6—psoriasis	5.01e-05	0.000599	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.95e-05	0.000592	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	4.94e-05	0.000591	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—IL6—psoriasis	4.93e-05	0.00059	CbGpPWpGaD
Dabrafenib—Asthenia—Methotrexate—psoriasis	4.91e-05	0.000202	CcSEcCtD
Dabrafenib—RAF1—Signaling by Interleukins—IL6—psoriasis	4.9e-05	0.000585	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.87e-05	0.000582	CbGpPWpGaD
Dabrafenib—Nausea—Prednisone—psoriasis	4.86e-05	0.0002	CcSEcCtD
Dabrafenib—Pruritus—Methotrexate—psoriasis	4.84e-05	0.000199	CcSEcCtD
Dabrafenib—BRAF—Signaling by FGFR in disease—IL6—psoriasis	4.77e-05	0.00057	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—STAT3—psoriasis	4.72e-05	0.000564	CbGpPWpGaD
Dabrafenib—Diarrhoea—Methotrexate—psoriasis	4.68e-05	0.000193	CcSEcCtD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—TYK2—psoriasis	4.67e-05	0.000558	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—IL6—psoriasis	4.66e-05	0.000557	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—SOCS1—psoriasis	4.65e-05	0.000556	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—STAT3—psoriasis	4.65e-05	0.000556	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Insulin receptor—IL6—psoriasis	4.62e-05	0.000553	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—STAT3—psoriasis	4.62e-05	0.000552	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL20—psoriasis	4.6e-05	0.00055	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—TYK2—psoriasis	4.59e-05	0.000549	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—TP53—psoriasis	4.56e-05	0.000545	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ITGAL—psoriasis	4.54e-05	0.000543	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CARM1—psoriasis	4.53e-05	0.000542	CbGpPWpGaD
Dabrafenib—Dizziness—Methotrexate—psoriasis	4.52e-05	0.000186	CcSEcCtD
Dabrafenib—RAF1—Focal Adhesion—VEGFA—psoriasis	4.5e-05	0.000539	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	4.49e-05	0.000536	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—SOCS1—psoriasis	4.47e-05	0.000534	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—TYK2—psoriasis	4.41e-05	0.000527	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IFNG—psoriasis	4.37e-05	0.000523	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	4.35e-05	0.00052	CbGpPWpGaD
Dabrafenib—Vomiting—Methotrexate—psoriasis	4.35e-05	0.000179	CcSEcCtD
Dabrafenib—Rash—Methotrexate—psoriasis	4.31e-05	0.000178	CcSEcCtD
Dabrafenib—Dermatitis—Methotrexate—psoriasis	4.31e-05	0.000177	CcSEcCtD
Dabrafenib—ABCB1—Allograft Rejection—VEGFA—psoriasis	4.29e-05	0.000512	CbGpPWpGaD
Dabrafenib—Headache—Methotrexate—psoriasis	4.28e-05	0.000176	CcSEcCtD
Dabrafenib—RAF1—MAPK Signaling Pathway—TNF—psoriasis	4.26e-05	0.000509	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—REL—psoriasis	4.25e-05	0.000508	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.24e-05	0.000507	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	4.22e-05	0.000505	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NDUFA5—psoriasis	4.22e-05	0.000504	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—IL6—psoriasis	4.19e-05	0.000501	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	4.18e-05	0.0005	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—TYK2—psoriasis	4.16e-05	0.000497	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IFNG—psoriasis	4.13e-05	0.000494	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFIH1—psoriasis	4.12e-05	0.000493	CbGpPWpGaD
Dabrafenib—Nausea—Methotrexate—psoriasis	4.06e-05	0.000167	CcSEcCtD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—VEGFA—psoriasis	3.99e-05	0.000477	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD4—psoriasis	3.99e-05	0.000477	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HLA-B—psoriasis	3.97e-05	0.000474	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD8A—psoriasis	3.96e-05	0.000473	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—IL6—psoriasis	3.96e-05	0.000473	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.93e-05	0.00047	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-C—psoriasis	3.91e-05	0.000467	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—LEP—psoriasis	3.89e-05	0.000465	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TNFAIP3—psoriasis	3.86e-05	0.000461	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	3.84e-05	0.00046	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-B—psoriasis	3.81e-05	0.000455	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—IL6—psoriasis	3.78e-05	0.000452	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TP53—psoriasis	3.76e-05	0.000449	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—IL6—psoriasis	3.72e-05	0.000445	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—IL6—psoriasis	3.7e-05	0.000443	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TNF—psoriasis	3.67e-05	0.000439	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NDUFA5—psoriasis	3.67e-05	0.000439	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.65e-05	0.000437	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—NFKB1—psoriasis	3.64e-05	0.000435	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP2S1—psoriasis	3.58e-05	0.000429	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—NFKB1—psoriasis	3.58e-05	0.000428	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—JUN—psoriasis	3.57e-05	0.000427	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—IL6—psoriasis	3.56e-05	0.000425	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—NOS2—psoriasis	3.55e-05	0.000425	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—IL6—psoriasis	3.54e-05	0.000423	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-A—psoriasis	3.53e-05	0.000422	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—IL6—psoriasis	3.52e-05	0.000421	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CRP—psoriasis	3.51e-05	0.000419	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—IL6—psoriasis	3.51e-05	0.000419	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—NFKB1—psoriasis	3.44e-05	0.000411	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	3.41e-05	0.000408	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	3.39e-05	0.000405	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—PPARG—psoriasis	3.39e-05	0.000405	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—IL6—psoriasis	3.3e-05	0.000394	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—IL6—psoriasis	3.3e-05	0.000394	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	3.3e-05	0.000394	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—STAT3—psoriasis	3.27e-05	0.000391	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.27e-05	0.000391	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—IL6—psoriasis	3.27e-05	0.000391	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	3.26e-05	0.000389	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—IL6—psoriasis	3.25e-05	0.000388	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-E—psoriasis	3.24e-05	0.000388	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—IL6—psoriasis	3.24e-05	0.000387	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-DRB1—psoriasis	3.23e-05	0.000386	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—IL6—psoriasis	3.22e-05	0.000386	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—STAT3—psoriasis	3.22e-05	0.000384	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—NFKBIA—psoriasis	3.2e-05	0.000382	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL20—psoriasis	3.18e-05	0.00038	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2S1—psoriasis	3.12e-05	0.000373	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—ICAM1—psoriasis	3.1e-05	0.00037	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—STAT3—psoriasis	3.09e-05	0.000369	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—NFKBIA—psoriasis	3.07e-05	0.000367	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CARM1—psoriasis	3.05e-05	0.000364	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TYK2—psoriasis	2.97e-05	0.000355	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—VEGFA—psoriasis	2.94e-05	0.000351	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	2.92e-05	0.000349	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HLA-A—psoriasis	2.86e-05	0.000342	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.85e-05	0.00034	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.82e-05	0.000337	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CARM1—psoriasis	2.82e-05	0.000337	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CAT—psoriasis	2.79e-05	0.000333	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SOCS1—psoriasis	2.71e-05	0.000324	CbGpPWpGaD
Dabrafenib—BRAF—Disease—APOE—psoriasis	2.67e-05	0.000319	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—TYK2—psoriasis	2.62e-05	0.000313	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SOCS1—psoriasis	2.53e-05	0.000303	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOS2—psoriasis	2.49e-05	0.000297	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.42e-05	0.000289	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD8A—psoriasis	2.4e-05	0.000287	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD4—psoriasis	2.37e-05	0.000283	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.33e-05	0.000279	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—NFKB1—psoriasis	2.31e-05	0.000276	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-B—psoriasis	2.31e-05	0.000276	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL6—psoriasis	2.28e-05	0.000273	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD4—psoriasis	2.27e-05	0.000272	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NDUFA5—psoriasis	2.26e-05	0.000271	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—IL6—psoriasis	2.25e-05	0.000269	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—APOE—psoriasis	2.17e-05	0.000259	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL6—psoriasis	2.16e-05	0.000258	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-A—psoriasis	2.14e-05	0.000256	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—JUN—psoriasis	2.12e-05	0.000253	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.12e-05	0.000253	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—VEGFA—psoriasis	2.1e-05	0.000251	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—STAT3—psoriasis	2.08e-05	0.000248	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VEGFA—psoriasis	2.06e-05	0.000246	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CRP—psoriasis	2.04e-05	0.000244	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—NFKB1—psoriasis	2.04e-05	0.000244	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TYK2—psoriasis	2.04e-05	0.000243	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—IL6—psoriasis	2.03e-05	0.000243	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HLA-A—psoriasis	1.98e-05	0.000236	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—NFKB1—psoriasis	1.96e-05	0.000234	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DRB1—psoriasis	1.96e-05	0.000234	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2S1—psoriasis	1.92e-05	0.00023	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PPARG—psoriasis	1.89e-05	0.000226	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.88e-05	0.000225	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ICAM1—psoriasis	1.88e-05	0.000224	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CAT—psoriasis	1.87e-05	0.000224	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—APOE—psoriasis	1.87e-05	0.000223	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—LEP—psoriasis	1.87e-05	0.000223	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NFKBIA—psoriasis	1.86e-05	0.000223	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APOE—psoriasis	1.85e-05	0.000221	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD4—psoriasis	1.84e-05	0.00022	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.81e-05	0.000217	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—psoriasis	1.8e-05	0.000215	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SOCS1—psoriasis	1.75e-05	0.000209	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CARM1—psoriasis	1.75e-05	0.000209	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NFKBIA—psoriasis	1.74e-05	0.000208	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CAT—psoriasis	1.74e-05	0.000207	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS2—psoriasis	1.72e-05	0.000206	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—TYK2—psoriasis	1.67e-05	0.0002	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.64e-05	0.000196	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.6e-05	0.000191	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—psoriasis	1.55e-05	0.000186	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TYK2—psoriasis	1.53e-05	0.000182	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CARM1—psoriasis	1.53e-05	0.000182	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—APOE—psoriasis	1.46e-05	0.000174	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL8—psoriasis	1.45e-05	0.000174	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—psoriasis	1.45e-05	0.000173	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNG—psoriasis	1.43e-05	0.000171	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TYK2—psoriasis	1.43e-05	0.00017	CbGpPWpGaD
Dabrafenib—BRAF—Disease—STAT3—psoriasis	1.43e-05	0.00017	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TYK2—psoriasis	1.41e-05	0.000168	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD4—psoriasis	1.38e-05	0.000165	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APOE—psoriasis	1.35e-05	0.000161	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—LEP—psoriasis	1.29e-05	0.000155	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOE—psoriasis	1.29e-05	0.000155	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—psoriasis	1.28e-05	0.000153	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—psoriasis	1.27e-05	0.000152	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARG—psoriasis	1.27e-05	0.000152	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL8—psoriasis	1.24e-05	0.000148	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—JUN—psoriasis	1.24e-05	0.000148	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NFKBIA—psoriasis	1.2e-05	0.000144	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NFKB1—psoriasis	1.19e-05	0.000142	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARG—psoriasis	1.17e-05	0.00014	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—JUN—psoriasis	1.15e-05	0.000138	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NFKB1—psoriasis	1.11e-05	0.000133	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CAT—psoriasis	1.08e-05	0.000129	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT3—psoriasis	1.07e-05	0.000128	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—psoriasis	1.01e-05	0.000121	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT3—psoriasis	9.98e-06	0.000119	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—psoriasis	9.96e-06	0.000119	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TYK2—psoriasis	9.86e-06	0.000118	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT3—psoriasis	9.86e-06	0.000118	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CARM1—psoriasis	9.4e-06	0.000112	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CAT—psoriasis	9.38e-06	0.000112	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL8—psoriasis	8.59e-06	0.000103	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOE—psoriasis	8.37e-06	0.0001	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—psoriasis	8.17e-06	9.76e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JUN—psoriasis	7.98e-06	9.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NFKB1—psoriasis	7.69e-06	9.19e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—psoriasis	7.62e-06	9.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—psoriasis	7.46e-06	8.92e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOE—psoriasis	7.29e-06	8.71e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARG—psoriasis	7.29e-06	8.71e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—psoriasis	6.98e-06	8.34e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—psoriasis	6.97e-06	8.34e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT3—psoriasis	6.91e-06	8.26e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—psoriasis	6.89e-06	8.24e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARG—psoriasis	6.35e-06	7.59e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CAT—psoriasis	5.78e-06	6.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—psoriasis	5.27e-06	6.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—psoriasis	4.82e-06	5.77e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOE—psoriasis	4.49e-06	5.37e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARG—psoriasis	3.91e-06	4.68e-05	CbGpPWpGaD
